Oncology
Latest news
826 articles · 20 / page
Genomic Evolution of Breast Cancer: How Acquired Gene Fusions Drive Metastatic Progression and Treatment Resistance
A multi-omics analysis from the AURORA program reveals that metastatic breast cancer carries a significantly higher burden of gene fusions than primary tumors. Acquired fusions, particularly involving ESR1, are linked to genomic instability
Erdafitinib Yields 55% Response Rate in FGFR-Altered Advanced Cholangiocarcinoma: Insights from a Pooled Phase 2 Analysis
A pooled analysis of the RAGNAR and LUC2001 trials demonstrates that erdafitinib provides a robust objective response rate of 55% and a median overall survival of 18.1 months in pretreated patients with FGFR-altered advanced cholangiocarcin
MAPK Pathway Mutations Drive Resistance to Ivosidenib in IDH1-Mutant Cholangiocarcinoma by Blunting Interferon Signaling
A comprehensive longitudinal ctDNA analysis of patients from the ClarIDHy phase III trial reveals that MAPK pathway alterations, including KRAS and NRAS mutations, are primary drivers of acquired resistance to ivosidenib by suppressing crit
Eribulin Demonstrates Clinical Efficacy in Taxane-Pretreated Metastatic Angiosarcoma and Epithelioid Hemangioendothelioma
A Phase 2 study reveals that eribulin, a non-taxane microtubule inhibitor, provides meaningful objective responses and disease stability in patients with rare vascular sarcomas, including those previously treated with taxanes.
Preserving the Immune Reservoir: Why Excessive Lymph Node Dissection Hinders Immunotherapy in Recurrent Biliary Tract Cancer
A multi-center study reveals that extensive dissection of non-metastatic tumor-draining lymph nodes reduces immunotherapy efficacy in recurrent biliary tract cancer by depleting crucial reservoirs of memory T cells and dendritic cells.
PET/CT-Guided Discontinuation of Immunotherapy in Metastatic Lung Cancer: A Paradigm Shift Toward Precision De-escalation
A landmark study from the nNGM reveals that PET/CT-guided discontinuation of immunotherapy in long-term lung cancer responders significantly improves survival and identifies second primary cancers, challenging the current practice of indefi
The Evolving Paradigm in High-Risk NMIBC: Critical Synthesis of Checkpoint Inhibitors and BCG Combination Therapy
A comprehensive meta-analysis of the POTOMAC, CREST, and ALBAN trials reveals that adding PD-(L)1 inhibitors to BCG improves event-free survival in high-risk NMIBC. However, increased toxicity and agent-specific variations in efficacy sugge
Molecular Imaging and PET-Guided Dose Escalation Revolutionize Salvage Radiotherapy: Insights from EMPIRE-1 and EMPIRE-2
The EMPIRE trials demonstrate that integrating molecular imaging and PET-guided dose escalation significantly improves event-free survival in patients requiring salvage radiotherapy for prostate cancer recurrence.
Multimodal AI Outperforms Clinical Nomograms in Predicting Metastasis for Post-Prostatectomy Biochemical Recurrence
A validated multimodal AI model using digital pathology and clinical data significantly improves risk stratification for prostate cancer patients with biochemical recurrence, identifying those who derive the greatest benefit from salvage ho
Audit and Feedback in NMIBC Surgery: Improved Documentation Does Not Translate to Better Clinical Outcomes
A global cluster randomized trial (RESECT) demonstrates that while audit and feedback improve surgical documentation in non-muscle-invasive bladder cancer, they fail to enhance detrusor muscle sampling, adjuvant chemotherapy use, or early r
The NanoKnife Revolution: A Non-Thermal Leap Forward in Precision Prostate Cancer Care
The PRESERVE trial demonstrates that Irreversible Electroporation (IRE) using the NanoKnife System is a safe and effective focal therapy for intermediate-risk prostate cancer, offering high success rates while preserving urinary and sexual
Stockholm3 Versus PSA in Prostate Cancer Screening: A Synthesis of 9-year Outcomes, Repeat Screening, and Multiethnic Validation
This review synthesizes long-term outcomes and multiethnic data demonstrating that the Stockholm3 test significantly improves the detection of aggressive prostate cancer while reducing overdiagnosis and unnecessary procedures compared to tr
Overcoming Resistance in ALK-Positive NSCLC: The Emergence of APG-2449 as a Novel FAK and Third-Generation TKI
This phase 1 trial identifies APG-2449 as a potent ALK/ROS1/FAK inhibitor. It shows significant efficacy in TKI-naïve and second-generation TKI-resistant ALK+ NSCLC, with high blood-brain barrier penetration and a manageable safety profile,
Systemic Atezolizumab and Intravesical BCG in High-Risk NMIBC: Lessons from the ALBAN (GETUG-AFU 37) Phase III Trial
The phase III ALBAN trial found no benefit in adding atezolizumab to BCG for BCG-naive high-risk NMIBC, emphasizing that immunotherapy benefits in this space are likely agent-specific and necessitate better biomarker-driven selection.
Datopotamab Deruxtecan Redefines Progression-Free Survival in HR+/HER2- Breast Cancer Despite Neutral Overall Survival Results
The final TROPION-Breast01 analysis confirms datopotamab deruxtecan’s superior progression-free survival over chemotherapy in HR+/HER2- breast cancer. While overall survival did not reach significance, likely due to subsequent ADC crossover
A New Era in Targeted Therapy: The Journey of Datopotamab Deruxtecan in HR+/HER2- Breast Cancer
Explore the Phase 3 TROPION-Breast01 study results, detailing how the antibody-drug conjugate datopotamab deruxtecan offers a superior alternative to standard chemotherapy in advanced HR+/HER2- breast cancer through improved progression-fre
Alectinib Sets a New Benchmark for Survival in ALK-Positive NSCLC: Final Results from the ALEX Trial
The final analysis of the Phase III ALEX trial confirms alectinib’s superior long-term efficacy over crizotinib, achieving a median overall survival of 81.1 months and significant intracranial benefits, solidifying its role as the first-lin
Improving Persistence: Dose Escalation Enhances Adjuvant Abemaciclib Tolerability in Early Breast Cancer
The Phase II TRADE trial demonstrates that a stepwise dose escalation of abemaciclib significantly improves drug tolerability and reduces early discontinuation rates in patients with high-risk HR-positive, HER2-negative early breast cancer
Dual Blockade of AKT and AR Pathways: Capivasertib Plus Abiraterone Significantly Extends rPFS in PTEN-Deficient mHSPC
The CAPItello-281 trial shows that capivasertib plus abiraterone improves radiographic progression-free survival by 7.5 months in PTEN-deficient metastatic hormone-sensitive prostate cancer, highlighting the importance of biomarker-driven t
National Expertise and Molecular Profiling Extend Survival in Cancer of Unknown Primary: Insights from the French CUP MTB
A French national study demonstrates that molecularly-guided treatments, facilitated by a dedicated multidisciplinary tumour board, significantly improve survival for patients with cancer of unknown primary, extending median overall surviva
Browse by specialty
Open language-specific specialty feeds and department pages.